Roberts Pharmaceutical Corp. of Eatontown, N.J., on Tuesdaysaid it has received final marketing approval from the HealthProtection Branch of Canada for its new drug Amatine fortreating orthostatic hypotension.
Roberts (NASDAQ:RPCX) will market Amatine in Canada throughan exclusive arrangement with Flint Laboratories Ltd., aCanadian subsidiary of The Boots Company plc of Nottingham,England.
Amatine belongs to the drug class known as alpha receptoragonists and is sold in Europe and Japan as a treatment fororthostatic hypotension and stress urinary incontinence.
Orthostatic hypotension involves the sudden drop in bloodpressure upon assuming an upright posture, resulting indizziness, weakness or unconsciousness. No other prescriptionproduct is approved in Canada to treat the disorder.
(c) 1997 American Health Consultants. All rights reserved.